TransCode Therapeutics, Inc. RNAZ 深 沪
等待开盘 10-14 09:30:00 美东时间
1.68
+0.050
+3.07%
华盛通- 最 高1.7799
- 今 开1.67
- 成交量 5.45万股
- 最 低 1.668
- 昨 收 1.63
- 总市值 2844.36万
- 52周最高 13.96
- 市盈率 静 --
- 换手率 0.32%
- 52周最低 1.52
- 委 比 26.36%
- 总股本 1693.07万
- 历史最高 5174400.00
- 量 比 1.23
- 振 幅 6.87%
- 历史最低 1.52
- 每 手 1
- 风险率 3.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic collab...
10-13 19:34
TransCode Therapeutics Announces Australia Acceptance Of Patent application, Japan's Issuance Of Notice Of Allowance For Its RNA-Based Therapeutic Platform Technologies
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced significant advancements in its global intellectual property portfolio, highlighted by (i) the acceptance of an Australian pate...
09-22 20:10
TransCode Therapeutics CFO retires
TransCode Therapeutics (RNAZ) said on Thursday that CFO Tom Fitzgerald is retiring from the company, effective immediately, after serving in the role since 2018. John Tattory will become interim CFO, ...
09-11 04:23
TransCode Therapeutics CFO Tom Fitzgerald Plans To Retire; John Tattory To Serve As Interim Finance Chief, Effective Immediately
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald. John Tattory, will serve as Interim Chief Financial Officer, eff...
09-11 04:22
TransCode Therapeutics Announces Leadership Transition
Tom Fitzgerald, Chief Financial Officer, Announces his Retirement John Tattory, to become Interim Chief Financial Officer BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. ...
09-11 04:10
美股夜盘 | TransCode Therapeutics, Inc.暴升21.66%，最新股价4.1美元
TransCode Therapeutics, Inc.暴升21.66%，报4.1美元
08-13 12:43
TransCode Therapeutics Updates Preferred Stock Governance Terms
TransCode Therapeutics ( ($RNAZ) ) has shared an announcement. TransCode Therap...
08-04 05:02
TransCode Therapeutics Shareholders Approve Key Capital Measures
TransCode Therapeutics ( ($RNAZ) ) has shared an update. On July 20, 2026, Tran...
07-21 04:51
TransCode Therapeutics Updates Preferred Stock Ownership Limits
An announcement from TransCode Therapeutics ( ($RNAZ) ) is now available. On Ju...
07-18 05:33
TransCode Highlights Progress of Lead RNA Cancer Therapeutic
An update from TransCode Therapeutics ( ($RNAZ) ) is now available. On June 18,...
06-18 20:39
